Shares of drug maker Pfizer Inc. (NYSE: PFE) were halted Wednesday afternoon at $32.29, down about 0.4% from the opening price. The company announced that its patent infringement case against a number of generic drug companies was invalidated by the U.S. District Court for the Eastern District of Virginia. Inc. (NYSE:PFE) stock opened at $31.99 in last session, and closed at $31.12, while the day range of PFE stock is $30.91-$32.02 .The stock showed a negative weekly performance of -4.13%.
Chardan Capital downgraded shares of Ariad Pharmaceuticals (NASDAQ:ARIA) from a buy rating to a neutral rating in a report issued on Wednesday, TheFlyOnTheWall.com reports. They currently have $9.00 target price on the stock. The analysts noted that the move was a valuation call. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) stock opened at $7.81, in last session and closed at $7.51, by loosed -3.35%. The 52 week range was $2.15-$23.00. Company’s market capitalization is $1.40 billion.
Arena Pharmaceuticals (NASDAQ:ARNA) was the recipient of unusually large options trading activity on Monday. Stock investors purchased 4,297 put options on the company, Analyst Ratings News reports. This is an increase of approximately 110% compared to the average volume of 2,050 put options. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) stock loosed -6.44% and finished the last session at $6.68.The EPS of the stock remained -0.09.Company’s market capitalization is $1.46 billion.
The OXiGENE Inc (NASDAQ:OXGN) recently announced positive top line results derived from randomised phase 2 clinical trial of Avastin (bevacizumab) with or without ZYBERESTAT for treating patients with recurring ovarian cancer. This study is known to be as Gynecologic Oncology Group Protocol 186I. This trial was conducted by GOG under its sponsors Cancer Therapy Evaluation Program of National Cancer Institute. This randomised trial is first of its kind to test antiangiogenic therapeutic agent combined with a vascular disrupting agent, without including any cytotoxic chemotherapy.This study was conducted on 107 patients in 67 clinical sites across US and were administered once in every three weeks to observe progression. It primarily met the endpoint statistically with increase in progression. OXiGENE Inc (NASDAQ:OXGN) stock opened the session at $4.64, and closed the session at $4.18. The 52 week range of the OXGN stock remained $1.96-$5.40 and the day range was $3.91-$4.87.